Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2009

View Archived Issues

ZymoGenetics divulges novel antipsoriatic ztnfr14 antagonists

New humaneered anti-factor B antibodies reported in recent Taligen patent

GSK reports novel AMPA receptor modulators with antipsychotic properties

Recent Merck & Co. patent discloses a new series of polypeptides with antibacterial properties

New Chlamydia vaccine patented by the Thrombosis Research Institute

UCB and Wilex sign strategic alliance to develop UCB's preclinical oncology portfolio

Array BioPharma initiates phase I clinical trial for MEK inhibitor ARRY-300

TopiGen reports phase II TPI-ASM-8 results in asthma patients

Cara commences phase II proof-of-concept trial in acute postoperative pain

Cytokinetics presents update on muscle biology research and development programs

Genzyme and Isis commence several mipomersen trials

Solace initiates phase IIa glial cell modulator trial in postherpetic neuralgia

InterMune reports results from ITMN-191 triple combination study

Ardea presents positive results from phase I RDEA-594 study

Synvista Therapeutics progresses phase II clinical trial program for alagebrium

Clinical investigation of Diasome's hepatic-directed vesicle-insulin advances

Mechanism behind leptin resistance clarified, possible treatments tested in vivo

FK-1706 shows promise in painful diabetic neuropathy

Cubist and Alnylam form strategic collaboration for RNAi therapeutics targeting RSV

Medtronic to acquire Ablation Frontiers for USD 225 million

Esteve signs research partnership for development of AIDS vaccine

Pharmasset and Roche agree with FDA on final design of phase IIb trial of R-7128 in HCV

ISMB authorizes completion of BioLineRx's phase I/II study of BL-1040 in MI

Novartis initiates dosing in phase IIb trial of Albuferon in chronic hepatitis C

Anthera completes enrollment and dosing in FRANCIS clinical trial of varespladib for ACS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...